Compare EVGN & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGN | SNOA |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | Israel | United States |
| Employees | N/A | 260 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.1M |
| IPO Year | 2013 | 2006 |
| Metric | EVGN | SNOA |
|---|---|---|
| Price | $0.28 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.2K | 37.4K |
| Earning Date | 11-19-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,529,000.00 |
| Revenue This Year | N/A | $22.44 |
| Revenue Next Year | $81.06 | $12.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.68 |
| 52 Week Low | $0.35 | $0.85 |
| 52 Week High | $1.28 | $3.95 |
| Indicator | EVGN | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 21.66 | 46.03 |
| Support Level | N/A | $1.03 |
| Resistance Level | $0.41 | $1.29 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.95 | 50.00 |
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.